nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—CYP2C8—Mometasone—atopic dermatitis	0.0834	0.134	CbGbCtD
Dabrafenib—ABCG2—Hydrocortisone—atopic dermatitis	0.05	0.0806	CbGbCtD
Dabrafenib—CYP2C8—Loratadine—atopic dermatitis	0.0479	0.0772	CbGbCtD
Dabrafenib—CYP3A4—Pimecrolimus—atopic dermatitis	0.0446	0.0719	CbGbCtD
Dabrafenib—ABCB1—Tacrolimus—atopic dermatitis	0.0443	0.0714	CbGbCtD
Dabrafenib—ABCB1—Loratadine—atopic dermatitis	0.0324	0.0522	CbGbCtD
Dabrafenib—ABCG2—Dexamethasone—atopic dermatitis	0.0311	0.0501	CbGbCtD
Dabrafenib—ABCB1—Methylprednisolone—atopic dermatitis	0.0297	0.0478	CbGbCtD
Dabrafenib—CYP2C8—Hydrocortisone—atopic dermatitis	0.0267	0.0429	CbGbCtD
Dabrafenib—CYP3A4—Tacrolimus—atopic dermatitis	0.0266	0.0428	CbGbCtD
Dabrafenib—CYP3A4—Loratadine—atopic dermatitis	0.0194	0.0313	CbGbCtD
Dabrafenib—ABCB1—Betamethasone—atopic dermatitis	0.0193	0.0311	CbGbCtD
Dabrafenib—ABCB1—Prednisolone—atopic dermatitis	0.019	0.0307	CbGbCtD
Dabrafenib—ABCB1—Hydrocortisone—atopic dermatitis	0.018	0.0291	CbGbCtD
Dabrafenib—ABCB1—Prednisone—atopic dermatitis	0.018	0.029	CbGbCtD
Dabrafenib—CYP3A4—Methylprednisolone—atopic dermatitis	0.0178	0.0286	CbGbCtD
Dabrafenib—CYP2C8—Dexamethasone—atopic dermatitis	0.0166	0.0267	CbGbCtD
Dabrafenib—CYP3A4—Triamcinolone—atopic dermatitis	0.0135	0.0217	CbGbCtD
Dabrafenib—CYP3A4—Betamethasone—atopic dermatitis	0.0116	0.0186	CbGbCtD
Dabrafenib—CYP3A4—Prednisolone—atopic dermatitis	0.0114	0.0184	CbGbCtD
Dabrafenib—ABCB1—Dexamethasone—atopic dermatitis	0.0112	0.0181	CbGbCtD
Dabrafenib—CYP3A4—Hydrocortisone—atopic dermatitis	0.0108	0.0174	CbGbCtD
Dabrafenib—CYP3A4—Prednisone—atopic dermatitis	0.0108	0.0173	CbGbCtD
Dabrafenib—CYP3A4—Dexamethasone—atopic dermatitis	0.00672	0.0108	CbGbCtD
Dabrafenib—Dizziness—Fluocinolone Acetonide—atopic dermatitis	0.000234	0.00081	CcSEcCtD
Dabrafenib—Nausea—Loratadine—atopic dermatitis	0.000234	0.00081	CcSEcCtD
Dabrafenib—Decreased appetite—Tacrolimus—atopic dermatitis	0.000234	0.000809	CcSEcCtD
Dabrafenib—Epistaxis—Triamcinolone—atopic dermatitis	0.000234	0.000809	CcSEcCtD
Dabrafenib—Dry skin—Prednisone—atopic dermatitis	0.000233	0.000806	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Tacrolimus—atopic dermatitis	0.000232	0.000804	CcSEcCtD
Dabrafenib—Connective tissue disorder—Hydrocortisone—atopic dermatitis	0.000232	0.000803	CcSEcCtD
Dabrafenib—Fatigue—Tacrolimus—atopic dermatitis	0.000232	0.000803	CcSEcCtD
Dabrafenib—Diarrhoea—Mometasone—atopic dermatitis	0.000231	0.0008	CcSEcCtD
Dabrafenib—Hypokalaemia—Prednisone—atopic dermatitis	0.000231	0.0008	CcSEcCtD
Dabrafenib—Constipation—Tacrolimus—atopic dermatitis	0.00023	0.000796	CcSEcCtD
Dabrafenib—Hyperglycaemia—Betamethasone—atopic dermatitis	0.000228	0.000787	CcSEcCtD
Dabrafenib—Hyperglycaemia—Dexamethasone—atopic dermatitis	0.000228	0.000787	CcSEcCtD
Dabrafenib—Vomiting—Fluocinolone Acetonide—atopic dermatitis	0.000225	0.000779	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Prednisone—atopic dermatitis	0.000224	0.000775	CcSEcCtD
Dabrafenib—Haemoglobin—Triamcinolone—atopic dermatitis	0.000224	0.000774	CcSEcCtD
Dabrafenib—Rash—Fluocinolone Acetonide—atopic dermatitis	0.000223	0.000772	CcSEcCtD
Dabrafenib—Haemoglobin—Methylprednisolone—atopic dermatitis	0.000223	0.000772	CcSEcCtD
Dabrafenib—Dermatitis—Fluocinolone Acetonide—atopic dermatitis	0.000223	0.000772	CcSEcCtD
Dabrafenib—Haemorrhage—Triamcinolone—atopic dermatitis	0.000223	0.00077	CcSEcCtD
Dabrafenib—Haemorrhage—Methylprednisolone—atopic dermatitis	0.000222	0.000768	CcSEcCtD
Dabrafenib—Headache—Fluocinolone Acetonide—atopic dermatitis	0.000222	0.000767	CcSEcCtD
Dabrafenib—Eye disorder—Hydrocortisone—atopic dermatitis	0.000221	0.000764	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Tacrolimus—atopic dermatitis	0.00022	0.000761	CcSEcCtD
Dabrafenib—Connective tissue disorder—Methylprednisolone—atopic dermatitis	0.000218	0.000755	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisolone—atopic dermatitis	0.000216	0.000748	CcSEcCtD
Dabrafenib—Pancreatitis—Prednisone—atopic dermatitis	0.000215	0.000745	CcSEcCtD
Dabrafenib—Vomiting—Mometasone—atopic dermatitis	0.000215	0.000744	CcSEcCtD
Dabrafenib—Immune system disorder—Hydrocortisone—atopic dermatitis	0.000213	0.000738	CcSEcCtD
Dabrafenib—Rash—Mometasone—atopic dermatitis	0.000213	0.000737	CcSEcCtD
Dabrafenib—Dermatitis—Mometasone—atopic dermatitis	0.000213	0.000737	CcSEcCtD
Dabrafenib—Abdominal pain—Tacrolimus—atopic dermatitis	0.000213	0.000736	CcSEcCtD
Dabrafenib—Body temperature increased—Tacrolimus—atopic dermatitis	0.000213	0.000736	CcSEcCtD
Dabrafenib—Headache—Mometasone—atopic dermatitis	0.000212	0.000733	CcSEcCtD
Dabrafenib—Arrhythmia—Hydrocortisone—atopic dermatitis	0.000211	0.00073	CcSEcCtD
Dabrafenib—Erythema—Prednisolone—atopic dermatitis	0.000211	0.000729	CcSEcCtD
Dabrafenib—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.00021	0.000728	CcSEcCtD
Dabrafenib—Eye disorder—Methylprednisolone—atopic dermatitis	0.000207	0.000718	CcSEcCtD
Dabrafenib—Mental disorder—Hydrocortisone—atopic dermatitis	0.000207	0.000716	CcSEcCtD
Dabrafenib—Erythema—Hydrocortisone—atopic dermatitis	0.000206	0.000712	CcSEcCtD
Dabrafenib—Malnutrition—Hydrocortisone—atopic dermatitis	0.000206	0.000712	CcSEcCtD
Dabrafenib—Neutropenia—Prednisone—atopic dermatitis	0.000205	0.00071	CcSEcCtD
Dabrafenib—Haemoglobin—Dexamethasone—atopic dermatitis	0.000203	0.000702	CcSEcCtD
Dabrafenib—Haemoglobin—Betamethasone—atopic dermatitis	0.000203	0.000702	CcSEcCtD
Dabrafenib—Haemorrhage—Dexamethasone—atopic dermatitis	0.000202	0.000698	CcSEcCtD
Dabrafenib—Haemorrhage—Betamethasone—atopic dermatitis	0.000202	0.000698	CcSEcCtD
Dabrafenib—Angiopathy—Methylprednisolone—atopic dermatitis	0.000201	0.000697	CcSEcCtD
Dabrafenib—Nausea—Mometasone—atopic dermatitis	0.000201	0.000695	CcSEcCtD
Dabrafenib—Immune system disorder—Methylprednisolone—atopic dermatitis	0.000201	0.000694	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methylprednisolone—atopic dermatitis	0.0002	0.000692	CcSEcCtD
Dabrafenib—Arrhythmia—Triamcinolone—atopic dermatitis	0.000199	0.000688	CcSEcCtD
Dabrafenib—Vision blurred—Prednisolone—atopic dermatitis	0.000199	0.000687	CcSEcCtD
Dabrafenib—Arrhythmia—Methylprednisolone—atopic dermatitis	0.000198	0.000686	CcSEcCtD
Dabrafenib—Hypersensitivity—Tacrolimus—atopic dermatitis	0.000198	0.000686	CcSEcCtD
Dabrafenib—Hyperglycaemia—Prednisone—atopic dermatitis	0.000198	0.000685	CcSEcCtD
Dabrafenib—Mental disorder—Methylprednisolone—atopic dermatitis	0.000195	0.000673	CcSEcCtD
Dabrafenib—Erythema—Triamcinolone—atopic dermatitis	0.000194	0.00067	CcSEcCtD
Dabrafenib—Malnutrition—Methylprednisolone—atopic dermatitis	0.000193	0.000668	CcSEcCtD
Dabrafenib—Erythema—Methylprednisolone—atopic dermatitis	0.000193	0.000668	CcSEcCtD
Dabrafenib—Asthenia—Tacrolimus—atopic dermatitis	0.000193	0.000668	CcSEcCtD
Dabrafenib—Pruritus—Tacrolimus—atopic dermatitis	0.00019	0.000659	CcSEcCtD
Dabrafenib—Eye disorder—Dexamethasone—atopic dermatitis	0.000189	0.000653	CcSEcCtD
Dabrafenib—Eye disorder—Betamethasone—atopic dermatitis	0.000189	0.000653	CcSEcCtD
Dabrafenib—Back pain—Triamcinolone—atopic dermatitis	0.000187	0.000648	CcSEcCtD
Dabrafenib—Diarrhoea—Tacrolimus—atopic dermatitis	0.000184	0.000637	CcSEcCtD
Dabrafenib—Angiopathy—Betamethasone—atopic dermatitis	0.000183	0.000634	CcSEcCtD
Dabrafenib—Angiopathy—Dexamethasone—atopic dermatitis	0.000183	0.000634	CcSEcCtD
Dabrafenib—Hypertension—Prednisolone—atopic dermatitis	0.000182	0.000629	CcSEcCtD
Dabrafenib—Arrhythmia—Betamethasone—atopic dermatitis	0.00018	0.000624	CcSEcCtD
Dabrafenib—Arrhythmia—Dexamethasone—atopic dermatitis	0.00018	0.000624	CcSEcCtD
Dabrafenib—Alopecia—Betamethasone—atopic dermatitis	0.000178	0.000617	CcSEcCtD
Dabrafenib—Alopecia—Dexamethasone—atopic dermatitis	0.000178	0.000617	CcSEcCtD
Dabrafenib—Dizziness—Tacrolimus—atopic dermatitis	0.000178	0.000616	CcSEcCtD
Dabrafenib—Hypertension—Hydrocortisone—atopic dermatitis	0.000178	0.000614	CcSEcCtD
Dabrafenib—Haemoglobin—Prednisone—atopic dermatitis	0.000177	0.000611	CcSEcCtD
Dabrafenib—Haemorrhage—Prednisone—atopic dermatitis	0.000176	0.000608	CcSEcCtD
Dabrafenib—Erythema—Betamethasone—atopic dermatitis	0.000176	0.000608	CcSEcCtD
Dabrafenib—Erythema—Dexamethasone—atopic dermatitis	0.000176	0.000608	CcSEcCtD
Dabrafenib—Myalgia—Hydrocortisone—atopic dermatitis	0.000175	0.000606	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.000174	0.000602	CcSEcCtD
Dabrafenib—Connective tissue disorder—Prednisone—atopic dermatitis	0.000173	0.000598	CcSEcCtD
Dabrafenib—Oedema—Prednisolone—atopic dermatitis	0.000172	0.000595	CcSEcCtD
Dabrafenib—Vomiting—Tacrolimus—atopic dermatitis	0.000171	0.000592	CcSEcCtD
Dabrafenib—Rash—Tacrolimus—atopic dermatitis	0.00017	0.000587	CcSEcCtD
Dabrafenib—Dermatitis—Tacrolimus—atopic dermatitis	0.00017	0.000586	CcSEcCtD
Dabrafenib—Cough—Triamcinolone—atopic dermatitis	0.000169	0.000585	CcSEcCtD
Dabrafenib—Headache—Tacrolimus—atopic dermatitis	0.000169	0.000583	CcSEcCtD
Dabrafenib—Oedema—Hydrocortisone—atopic dermatitis	0.000168	0.000581	CcSEcCtD
Dabrafenib—Hypertension—Triamcinolone—atopic dermatitis	0.000167	0.000578	CcSEcCtD
Dabrafenib—Hypertension—Methylprednisolone—atopic dermatitis	0.000167	0.000577	CcSEcCtD
Dabrafenib—Infection—Hydrocortisone—atopic dermatitis	0.000167	0.000577	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisolone—atopic dermatitis	0.000166	0.000575	CcSEcCtD
Dabrafenib—Myalgia—Triamcinolone—atopic dermatitis	0.000165	0.00057	CcSEcCtD
Dabrafenib—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000165	0.000569	CcSEcCtD
Dabrafenib—Arthralgia—Methylprednisolone—atopic dermatitis	0.000165	0.000569	CcSEcCtD
Dabrafenib—Myalgia—Methylprednisolone—atopic dermatitis	0.000165	0.000569	CcSEcCtD
Dabrafenib—Eye disorder—Prednisone—atopic dermatitis	0.000164	0.000568	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000163	0.000565	CcSEcCtD
Dabrafenib—Skin disorder—Hydrocortisone—atopic dermatitis	0.000163	0.000564	CcSEcCtD
Dabrafenib—Hyperhidrosis—Hydrocortisone—atopic dermatitis	0.000162	0.000561	CcSEcCtD
Dabrafenib—Dry mouth—Triamcinolone—atopic dermatitis	0.000161	0.000558	CcSEcCtD
Dabrafenib—Nausea—Tacrolimus—atopic dermatitis	0.00016	0.000553	CcSEcCtD
Dabrafenib—Angiopathy—Prednisone—atopic dermatitis	0.00016	0.000552	CcSEcCtD
Dabrafenib—Immune system disorder—Prednisone—atopic dermatitis	0.000159	0.000549	CcSEcCtD
Dabrafenib—Oedema—Triamcinolone—atopic dermatitis	0.000158	0.000547	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisone—atopic dermatitis	0.000157	0.000543	CcSEcCtD
Dabrafenib—Infection—Triamcinolone—atopic dermatitis	0.000157	0.000543	CcSEcCtD
Dabrafenib—Hypotension—Hydrocortisone—atopic dermatitis	0.000157	0.000543	CcSEcCtD
Dabrafenib—Infection—Methylprednisolone—atopic dermatitis	0.000157	0.000542	CcSEcCtD
Dabrafenib—Insomnia—Prednisolone—atopic dermatitis	0.000155	0.000538	CcSEcCtD
Dabrafenib—Alopecia—Prednisone—atopic dermatitis	0.000155	0.000537	CcSEcCtD
Dabrafenib—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.000155	0.000535	CcSEcCtD
Dabrafenib—Mental disorder—Prednisone—atopic dermatitis	0.000154	0.000533	CcSEcCtD
Dabrafenib—Skin disorder—Methylprednisolone—atopic dermatitis	0.000153	0.00053	CcSEcCtD
Dabrafenib—Malnutrition—Prednisone—atopic dermatitis	0.000153	0.000529	CcSEcCtD
Dabrafenib—Erythema—Prednisone—atopic dermatitis	0.000153	0.000529	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	0.000153	0.000529	CcSEcCtD
Dabrafenib—Hyperhidrosis—Triamcinolone—atopic dermatitis	0.000153	0.000529	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methylprednisolone—atopic dermatitis	0.000152	0.000527	CcSEcCtD
Dabrafenib—Insomnia—Hydrocortisone—atopic dermatitis	0.000152	0.000525	CcSEcCtD
Dabrafenib—Hypertension—Dexamethasone—atopic dermatitis	0.000152	0.000525	CcSEcCtD
Dabrafenib—Hypertension—Betamethasone—atopic dermatitis	0.000152	0.000525	CcSEcCtD
Dabrafenib—Myalgia—Dexamethasone—atopic dermatitis	0.00015	0.000518	CcSEcCtD
Dabrafenib—Myalgia—Betamethasone—atopic dermatitis	0.00015	0.000518	CcSEcCtD
Dabrafenib—Hypotension—Methylprednisolone—atopic dermatitis	0.000147	0.00051	CcSEcCtD
Dabrafenib—Decreased appetite—Hydrocortisone—atopic dermatitis	0.000146	0.000505	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000145	0.000501	CcSEcCtD
Dabrafenib—Fatigue—Hydrocortisone—atopic dermatitis	0.000145	0.000501	CcSEcCtD
Dabrafenib—Vision blurred—Prednisone—atopic dermatitis	0.000144	0.000499	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	0.000144	0.000498	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	0.000144	0.000497	CcSEcCtD
Dabrafenib—Oedema—Dexamethasone—atopic dermatitis	0.000143	0.000496	CcSEcCtD
Dabrafenib—Oedema—Betamethasone—atopic dermatitis	0.000143	0.000496	CcSEcCtD
Dabrafenib—Insomnia—Triamcinolone—atopic dermatitis	0.000143	0.000495	CcSEcCtD
Dabrafenib—Insomnia—Methylprednisolone—atopic dermatitis	0.000143	0.000493	CcSEcCtD
Dabrafenib—Infection—Betamethasone—atopic dermatitis	0.000143	0.000493	CcSEcCtD
Dabrafenib—Infection—Dexamethasone—atopic dermatitis	0.000143	0.000493	CcSEcCtD
Dabrafenib—Anaemia—Prednisone—atopic dermatitis	0.000141	0.000489	CcSEcCtD
Dabrafenib—Nervous system disorder—Betamethasone—atopic dermatitis	0.000141	0.000487	CcSEcCtD
Dabrafenib—Nervous system disorder—Dexamethasone—atopic dermatitis	0.000141	0.000487	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dexamethasone—atopic dermatitis	0.00014	0.000486	CcSEcCtD
Dabrafenib—Thrombocytopenia—Betamethasone—atopic dermatitis	0.00014	0.000486	CcSEcCtD
Dabrafenib—Hyperhidrosis—Dexamethasone—atopic dermatitis	0.000139	0.00048	CcSEcCtD
Dabrafenib—Hyperhidrosis—Betamethasone—atopic dermatitis	0.000139	0.00048	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	0.000137	0.000475	CcSEcCtD
Dabrafenib—Fatigue—Triamcinolone—atopic dermatitis	0.000136	0.000471	CcSEcCtD
Dabrafenib—Fatigue—Methylprednisolone—atopic dermatitis	0.000136	0.00047	CcSEcCtD
Dabrafenib—Hypotension—Betamethasone—atopic dermatitis	0.000134	0.000464	CcSEcCtD
Dabrafenib—Hypotension—Dexamethasone—atopic dermatitis	0.000134	0.000464	CcSEcCtD
Dabrafenib—Abdominal pain—Hydrocortisone—atopic dermatitis	0.000133	0.000459	CcSEcCtD
Dabrafenib—Body temperature increased—Hydrocortisone—atopic dermatitis	0.000133	0.000459	CcSEcCtD
Dabrafenib—Hypertension—Prednisone—atopic dermatitis	0.000132	0.000457	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	0.000131	0.000452	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	0.000131	0.000452	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—atopic dermatitis	0.00013	0.000451	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—atopic dermatitis	0.00013	0.000451	CcSEcCtD
Dabrafenib—Insomnia—Dexamethasone—atopic dermatitis	0.00013	0.000449	CcSEcCtD
Dabrafenib—Insomnia—Betamethasone—atopic dermatitis	0.00013	0.000449	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	0.000129	0.000448	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	0.000129	0.000446	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisolone—atopic dermatitis	0.000127	0.000438	CcSEcCtD
Dabrafenib—Body temperature increased—Triamcinolone—atopic dermatitis	0.000125	0.000432	CcSEcCtD
Dabrafenib—Oedema—Prednisone—atopic dermatitis	0.000125	0.000432	CcSEcCtD
Dabrafenib—Abdominal pain—Methylprednisolone—atopic dermatitis	0.000125	0.000431	CcSEcCtD
Dabrafenib—Decreased appetite—Dexamethasone—atopic dermatitis	0.000125	0.000431	CcSEcCtD
Dabrafenib—Decreased appetite—Betamethasone—atopic dermatitis	0.000125	0.000431	CcSEcCtD
Dabrafenib—Infection—Prednisone—atopic dermatitis	0.000124	0.000429	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Betamethasone—atopic dermatitis	0.000124	0.000428	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	0.000124	0.000428	CcSEcCtD
Dabrafenib—Hypersensitivity—Hydrocortisone—atopic dermatitis	0.000124	0.000428	CcSEcCtD
Dabrafenib—Fatigue—Betamethasone—atopic dermatitis	0.000124	0.000428	CcSEcCtD
Dabrafenib—Fatigue—Dexamethasone—atopic dermatitis	0.000124	0.000428	CcSEcCtD
Dabrafenib—Nervous system disorder—Prednisone—atopic dermatitis	0.000123	0.000424	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—atopic dermatitis	0.000121	0.00042	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisone—atopic dermatitis	0.000121	0.000418	CcSEcCtD
Dabrafenib—Asthenia—Hydrocortisone—atopic dermatitis	0.00012	0.000417	CcSEcCtD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—NGF—atopic dermatitis	0.000119	0.00132	CbGpPWpGaD
Dabrafenib—Pruritus—Hydrocortisone—atopic dermatitis	0.000119	0.000411	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Betamethasone—atopic dermatitis	0.000117	0.000406	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dexamethasone—atopic dermatitis	0.000117	0.000406	CcSEcCtD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—MAPK8—atopic dermatitis	0.000117	0.0013	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—MAPK8—atopic dermatitis	0.000117	0.0013	CbGpPWpGaD
Dabrafenib—BRAF—Disease—GLB1—atopic dermatitis	0.000117	0.00129	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Triamcinolone—atopic dermatitis	0.000116	0.000403	CcSEcCtD
Dabrafenib—Hypersensitivity—Methylprednisolone—atopic dermatitis	0.000116	0.000402	CcSEcCtD
Dabrafenib—LIMK1—Immune System—CD79A—atopic dermatitis	0.000116	0.00129	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL1B—atopic dermatitis	0.000115	0.00128	CbGpPWpGaD
Dabrafenib—Diarrhoea—Hydrocortisone—atopic dermatitis	0.000115	0.000397	CcSEcCtD
Dabrafenib—BRAF—MAPK Signaling Pathway—IL1B—atopic dermatitis	0.000114	0.00127	CbGpPWpGaD
Dabrafenib—Musculoskeletal discomfort—Prednisone—atopic dermatitis	0.000114	0.000394	CcSEcCtD
Dabrafenib—Dizziness—Prednisolone—atopic dermatitis	0.000114	0.000393	CcSEcCtD
Dabrafenib—Asthenia—Triamcinolone—atopic dermatitis	0.000113	0.000392	CcSEcCtD
Dabrafenib—Abdominal pain—Dexamethasone—atopic dermatitis	0.000113	0.000392	CcSEcCtD
Dabrafenib—Abdominal pain—Betamethasone—atopic dermatitis	0.000113	0.000392	CcSEcCtD
Dabrafenib—Body temperature increased—Dexamethasone—atopic dermatitis	0.000113	0.000392	CcSEcCtD
Dabrafenib—Body temperature increased—Betamethasone—atopic dermatitis	0.000113	0.000392	CcSEcCtD
Dabrafenib—Asthenia—Methylprednisolone—atopic dermatitis	0.000113	0.000391	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—atopic dermatitis	0.000113	0.000391	CcSEcCtD
Dabrafenib—RAF1—Hemostasis—SELE—atopic dermatitis	0.000112	0.00125	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL1B—atopic dermatitis	0.000112	0.00125	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL22—atopic dermatitis	0.000112	0.00125	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—MAPK8—atopic dermatitis	0.000112	0.00125	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CASP8—atopic dermatitis	0.000112	0.00125	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL2—atopic dermatitis	0.000112	0.00124	CbGpPWpGaD
Dabrafenib—Pruritus—Triamcinolone—atopic dermatitis	0.000112	0.000387	CcSEcCtD
Dabrafenib—Pruritus—Methylprednisolone—atopic dermatitis	0.000112	0.000386	CcSEcCtD
Dabrafenib—Dizziness—Hydrocortisone—atopic dermatitis	0.000111	0.000384	CcSEcCtD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—NFKBIA—atopic dermatitis	0.000111	0.00123	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FCER1A—atopic dermatitis	0.00011	0.00123	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—NFKBIA—atopic dermatitis	0.000109	0.00121	CbGpPWpGaD
Dabrafenib—Decreased appetite—Prednisone—atopic dermatitis	0.000109	0.000376	CcSEcCtD
Dabrafenib—Rash—Prednisolone—atopic dermatitis	0.000108	0.000375	CcSEcCtD
Dabrafenib—Dermatitis—Prednisolone—atopic dermatitis	0.000108	0.000375	CcSEcCtD
Dabrafenib—RAF1—SHP2 signaling—IL6—atopic dermatitis	0.000108	0.0012	CbGpPWpGaD
Dabrafenib—Diarrhoea—Methylprednisolone—atopic dermatitis	0.000108	0.000373	CcSEcCtD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—MAPK8—atopic dermatitis	0.000108	0.0012	CbGpPWpGaD
Dabrafenib—Fatigue—Prednisone—atopic dermatitis	0.000108	0.000372	CcSEcCtD
Dabrafenib—Headache—Prednisolone—atopic dermatitis	0.000108	0.000372	CcSEcCtD
Dabrafenib—Constipation—Prednisone—atopic dermatitis	0.000107	0.000369	CcSEcCtD
Dabrafenib—RAF1—Innate Immune System—STAT6—atopic dermatitis	0.000107	0.00119	CbGpPWpGaD
Dabrafenib—Vomiting—Hydrocortisone—atopic dermatitis	0.000107	0.000369	CcSEcCtD
Dabrafenib—Rash—Hydrocortisone—atopic dermatitis	0.000106	0.000366	CcSEcCtD
Dabrafenib—Dermatitis—Hydrocortisone—atopic dermatitis	0.000106	0.000366	CcSEcCtD
Dabrafenib—RAF1—ErbB1 downstream signaling—MAPK8—atopic dermatitis	0.000105	0.00117	CbGpPWpGaD
Dabrafenib—Headache—Hydrocortisone—atopic dermatitis	0.000105	0.000364	CcSEcCtD
Dabrafenib—BRAF—MAPK Signaling Pathway—MAPK8—atopic dermatitis	0.000105	0.00116	CbGpPWpGaD
Dabrafenib—Dizziness—Triamcinolone—atopic dermatitis	0.000105	0.000362	CcSEcCtD
Dabrafenib—Dizziness—Methylprednisolone—atopic dermatitis	0.000104	0.000361	CcSEcCtD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	0.000104	0.00116	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—CASP8—atopic dermatitis	0.000104	0.00116	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CARD11—atopic dermatitis	0.000104	0.00115	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FCER2—atopic dermatitis	0.000103	0.00115	CbGpPWpGaD
Dabrafenib—Asthenia—Betamethasone—atopic dermatitis	0.000103	0.000356	CcSEcCtD
Dabrafenib—Asthenia—Dexamethasone—atopic dermatitis	0.000103	0.000356	CcSEcCtD
Dabrafenib—RAF1—Immune System—MS4A2—atopic dermatitis	0.000103	0.00114	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Prednisone—atopic dermatitis	0.000102	0.000353	CcSEcCtD
Dabrafenib—Nausea—Prednisolone—atopic dermatitis	0.000102	0.000353	CcSEcCtD
Dabrafenib—Pruritus—Dexamethasone—atopic dermatitis	0.000101	0.000351	CcSEcCtD
Dabrafenib—Pruritus—Betamethasone—atopic dermatitis	0.000101	0.000351	CcSEcCtD
Dabrafenib—Vomiting—Triamcinolone—atopic dermatitis	0.000101	0.000348	CcSEcCtD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL18—atopic dermatitis	0.0001	0.00112	CbGpPWpGaD
Dabrafenib—Vomiting—Methylprednisolone—atopic dermatitis	0.0001	0.000347	CcSEcCtD
Dabrafenib—RAF1—Signaling by GPCR—CCL27—atopic dermatitis	0.0001	0.00111	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	0.0001	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CARD11—atopic dermatitis	9.98e-05	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—atopic dermatitis	9.98e-05	0.00111	CbGpPWpGaD
Dabrafenib—Nausea—Hydrocortisone—atopic dermatitis	9.97e-05	0.000345	CcSEcCtD
Dabrafenib—Rash—Triamcinolone—atopic dermatitis	9.97e-05	0.000345	CcSEcCtD
Dabrafenib—Dermatitis—Triamcinolone—atopic dermatitis	9.96e-05	0.000344	CcSEcCtD
Dabrafenib—Rash—Methylprednisolone—atopic dermatitis	9.95e-05	0.000344	CcSEcCtD
Dabrafenib—Dermatitis—Methylprednisolone—atopic dermatitis	9.94e-05	0.000344	CcSEcCtD
Dabrafenib—Headache—Triamcinolone—atopic dermatitis	9.9e-05	0.000343	CcSEcCtD
Dabrafenib—Headache—Methylprednisolone—atopic dermatitis	9.88e-05	0.000342	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—atopic dermatitis	9.88e-05	0.000342	CcSEcCtD
Dabrafenib—Abdominal pain—Prednisone—atopic dermatitis	9.88e-05	0.000342	CcSEcCtD
Dabrafenib—Diarrhoea—Dexamethasone—atopic dermatitis	9.82e-05	0.000339	CcSEcCtD
Dabrafenib—Diarrhoea—Betamethasone—atopic dermatitis	9.82e-05	0.000339	CcSEcCtD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—IL6—atopic dermatitis	9.73e-05	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	9.66e-05	0.00107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL22—atopic dermatitis	9.6e-05	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—NCAM signaling for neurite out-growth—IL6—atopic dermatitis	9.53e-05	0.00106	CbGpPWpGaD
Dabrafenib—Dizziness—Dexamethasone—atopic dermatitis	9.49e-05	0.000328	CcSEcCtD
Dabrafenib—Dizziness—Betamethasone—atopic dermatitis	9.49e-05	0.000328	CcSEcCtD
Dabrafenib—BRAF—Focal Adhesion—MAPK8—atopic dermatitis	9.49e-05	0.00105	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL18—atopic dermatitis	9.48e-05	0.00105	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GLB1—atopic dermatitis	9.46e-05	0.00105	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	9.4e-05	0.00104	CbGpPWpGaD
Dabrafenib—Nausea—Triamcinolone—atopic dermatitis	9.39e-05	0.000325	CcSEcCtD
Dabrafenib—Nausea—Methylprednisolone—atopic dermatitis	9.37e-05	0.000324	CcSEcCtD
Dabrafenib—LIMK1—Immune System—CD8A—atopic dermatitis	9.34e-05	0.00104	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—TNF—atopic dermatitis	9.28e-05	0.00103	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CD4—atopic dermatitis	9.21e-05	0.00102	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Prednisone—atopic dermatitis	9.2e-05	0.000318	CcSEcCtD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—MAPK8—atopic dermatitis	9.17e-05	0.00102	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—DEFB1—atopic dermatitis	9.15e-05	0.00102	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—NGF—atopic dermatitis	9.15e-05	0.00102	CbGpPWpGaD
Dabrafenib—Vomiting—Dexamethasone—atopic dermatitis	9.12e-05	0.000315	CcSEcCtD
Dabrafenib—Vomiting—Betamethasone—atopic dermatitis	9.12e-05	0.000315	CcSEcCtD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	9.1e-05	0.00101	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ADSL—atopic dermatitis	9.07e-05	0.00101	CbGpPWpGaD
Dabrafenib—Rash—Betamethasone—atopic dermatitis	9.04e-05	0.000313	CcSEcCtD
Dabrafenib—Rash—Dexamethasone—atopic dermatitis	9.04e-05	0.000313	CcSEcCtD
Dabrafenib—Dermatitis—Dexamethasone—atopic dermatitis	9.04e-05	0.000313	CcSEcCtD
Dabrafenib—Dermatitis—Betamethasone—atopic dermatitis	9.04e-05	0.000313	CcSEcCtD
Dabrafenib—Headache—Dexamethasone—atopic dermatitis	8.99e-05	0.000311	CcSEcCtD
Dabrafenib—Headache—Betamethasone—atopic dermatitis	8.99e-05	0.000311	CcSEcCtD
Dabrafenib—RAF1—Signaling by GPCR—CCL17—atopic dermatitis	8.98e-05	0.000998	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CASP8—atopic dermatitis	8.98e-05	0.000997	CbGpPWpGaD
Dabrafenib—Asthenia—Prednisone—atopic dermatitis	8.96e-05	0.00031	CcSEcCtD
Dabrafenib—Pruritus—Prednisone—atopic dermatitis	8.84e-05	0.000306	CcSEcCtD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—MAPK8—atopic dermatitis	8.78e-05	0.000975	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL27—atopic dermatitis	8.55e-05	0.00095	CbGpPWpGaD
Dabrafenib—Diarrhoea—Prednisone—atopic dermatitis	8.55e-05	0.000296	CcSEcCtD
Dabrafenib—RAF1—Hemostasis—IL5—atopic dermatitis	8.52e-05	0.000947	CbGpPWpGaD
Dabrafenib—Nausea—Betamethasone—atopic dermatitis	8.52e-05	0.000295	CcSEcCtD
Dabrafenib—Nausea—Dexamethasone—atopic dermatitis	8.52e-05	0.000295	CcSEcCtD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	8.42e-05	0.000935	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TNF—atopic dermatitis	8.28e-05	0.00092	CbGpPWpGaD
Dabrafenib—Dizziness—Prednisone—atopic dermatitis	8.26e-05	0.000286	CcSEcCtD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	8.21e-05	0.000911	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—MAPK8—atopic dermatitis	8.19e-05	0.00091	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CASP1—atopic dermatitis	8.09e-05	0.000899	CbGpPWpGaD
Dabrafenib—RAF1—Disease—GLB1—atopic dermatitis	8.06e-05	0.000895	CbGpPWpGaD
Dabrafenib—RAF1—IRS-mediated signalling—IL6—atopic dermatitis	7.98e-05	0.000886	CbGpPWpGaD
Dabrafenib—Vomiting—Prednisone—atopic dermatitis	7.94e-05	0.000275	CcSEcCtD
Dabrafenib—LIMK1—Axon guidance—IL6—atopic dermatitis	7.9e-05	0.000878	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—IL1B—atopic dermatitis	7.9e-05	0.000877	CbGpPWpGaD
Dabrafenib—Rash—Prednisone—atopic dermatitis	7.88e-05	0.000272	CcSEcCtD
Dabrafenib—Dermatitis—Prednisone—atopic dermatitis	7.87e-05	0.000272	CcSEcCtD
Dabrafenib—Headache—Prednisone—atopic dermatitis	7.83e-05	0.000271	CcSEcCtD
Dabrafenib—BRAF—Disease—SLC11A1—atopic dermatitis	7.81e-05	0.000867	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—MAPK8—atopic dermatitis	7.8e-05	0.000867	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events—IL6—atopic dermatitis	7.76e-05	0.000862	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events triggered by IGF1R—IL6—atopic dermatitis	7.69e-05	0.000854	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL17—atopic dermatitis	7.67e-05	0.000852	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IFNG—atopic dermatitis	7.64e-05	0.000848	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—IL6—atopic dermatitis	7.62e-05	0.000846	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—NFKBIA—atopic dermatitis	7.54e-05	0.000838	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—MAPK8—atopic dermatitis	7.53e-05	0.000836	CbGpPWpGaD
Dabrafenib—RAF1—Insulin receptor signalling cascade—IL6—atopic dermatitis	7.49e-05	0.000831	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—IL6—atopic dermatitis	7.49e-05	0.000831	CbGpPWpGaD
Dabrafenib—RAF1—IGF1R signaling cascade—IL6—atopic dermatitis	7.49e-05	0.000831	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—MAPK8—atopic dermatitis	7.46e-05	0.000828	CbGpPWpGaD
Dabrafenib—Nausea—Prednisone—atopic dermatitis	7.42e-05	0.000257	CcSEcCtD
Dabrafenib—RAF1—Innate Immune System—TLR2—atopic dermatitis	7.32e-05	0.000813	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KIF3A—atopic dermatitis	7.32e-05	0.000813	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—NFKBIA—atopic dermatitis	7.24e-05	0.000805	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL11—atopic dermatitis	7.24e-05	0.000804	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—MAPK8—atopic dermatitis	7.24e-05	0.000804	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FCER2—atopic dermatitis	7.14e-05	0.000793	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CXCL8—atopic dermatitis	7.1e-05	0.000789	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TNF—atopic dermatitis	6.99e-05	0.000776	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—MAPK8—atopic dermatitis	6.95e-05	0.000771	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	6.9e-05	0.000766	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—IL6—atopic dermatitis	6.88e-05	0.000764	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—MAPK8—atopic dermatitis	6.84e-05	0.00076	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KIF3A—atopic dermatitis	6.84e-05	0.000759	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL1B—atopic dermatitis	6.81e-05	0.000756	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL2—atopic dermatitis	6.78e-05	0.000754	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL6—atopic dermatitis	6.74e-05	0.000748	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	6.71e-05	0.000745	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL22—atopic dermatitis	6.64e-05	0.000737	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—atopic dermatitis	6.63e-05	0.000737	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD79A—atopic dermatitis	6.61e-05	0.000734	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL6—atopic dermatitis	6.58e-05	0.000731	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—MAPK8—atopic dermatitis	6.56e-05	0.000729	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—PPARA—atopic dermatitis	6.56e-05	0.000728	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	6.54e-05	0.000726	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CASP8—atopic dermatitis	6.53e-05	0.000726	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—IL6—atopic dermatitis	6.41e-05	0.000712	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GLB1—atopic dermatitis	6.36e-05	0.000706	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—IL2—atopic dermatitis	6.32e-05	0.000702	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—IL6—atopic dermatitis	6.26e-05	0.000696	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT6—atopic dermatitis	6.22e-05	0.000691	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—IL6—atopic dermatitis	6.22e-05	0.000691	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CMA1—atopic dermatitis	6.18e-05	0.000687	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL11—atopic dermatitis	6.18e-05	0.000687	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ADSL—atopic dermatitis	6.1e-05	0.000677	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CARD11—atopic dermatitis	6.05e-05	0.000672	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL27—atopic dermatitis	5.92e-05	0.000657	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR3—atopic dermatitis	5.9e-05	0.000656	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GLB1—atopic dermatitis	5.89e-05	0.000654	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IFNG—atopic dermatitis	5.88e-05	0.000653	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT6—atopic dermatitis	5.81e-05	0.000646	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—PPARA—atopic dermatitis	5.8e-05	0.000645	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—atopic dermatitis	5.73e-05	0.000636	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	5.68e-05	0.000631	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ADSL—atopic dermatitis	5.65e-05	0.000627	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—IL6—atopic dermatitis	5.64e-05	0.000627	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IFNG—atopic dermatitis	5.56e-05	0.000617	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—PPARA—atopic dermatitis	5.51e-05	0.000612	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SLC11A1—atopic dermatitis	5.4e-05	0.0006	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD4—atopic dermatitis	5.37e-05	0.000596	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD8A—atopic dermatitis	5.33e-05	0.000592	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—IL6—atopic dermatitis	5.32e-05	0.000591	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL17—atopic dermatitis	5.31e-05	0.000589	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TAC1—atopic dermatitis	5.26e-05	0.000584	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NPS—atopic dermatitis	5.26e-05	0.000584	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL1B—atopic dermatitis	5.25e-05	0.000583	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL2—atopic dermatitis	5.23e-05	0.000581	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	5.17e-05	0.000574	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCR3—atopic dermatitis	5.16e-05	0.000573	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—atopic dermatitis	5.09e-05	0.000565	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR3—atopic dermatitis	5.04e-05	0.00056	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—atopic dermatitis	5.01e-05	0.000556	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—atopic dermatitis	4.98e-05	0.000553	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL1B—atopic dermatitis	4.96e-05	0.00055	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—atopic dermatitis	4.94e-05	0.000549	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL2—atopic dermatitis	4.94e-05	0.000548	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	4.91e-05	0.000546	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL5—atopic dermatitis	4.89e-05	0.000543	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.84e-05	0.000538	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—atopic dermatitis	4.78e-05	0.000531	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—atopic dermatitis	4.76e-05	0.000529	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—atopic dermatitis	4.74e-05	0.000526	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—MAPK8—atopic dermatitis	4.73e-05	0.000526	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIF3A—atopic dermatitis	4.73e-05	0.000525	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CASP1—atopic dermatitis	4.71e-05	0.000524	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—atopic dermatitis	4.71e-05	0.000524	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.68e-05	0.00052	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	4.63e-05	0.000515	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	4.55e-05	0.000506	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—MAPK8—atopic dermatitis	4.54e-05	0.000505	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TAC1—atopic dermatitis	4.49e-05	0.000499	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NPS—atopic dermatitis	4.49e-05	0.000499	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL5—atopic dermatitis	4.47e-05	0.000496	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	4.44e-05	0.000493	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—atopic dermatitis	4.44e-05	0.000493	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—atopic dermatitis	4.44e-05	0.000493	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	4.43e-05	0.000492	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.41e-05	0.000489	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCR3—atopic dermatitis	4.41e-05	0.000489	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—atopic dermatitis	4.4e-05	0.000488	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—atopic dermatitis	4.37e-05	0.000485	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—atopic dermatitis	4.36e-05	0.000484	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—atopic dermatitis	4.34e-05	0.000482	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NFKBIA—atopic dermatitis	4.3e-05	0.000478	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CMA1—atopic dermatitis	4.28e-05	0.000475	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL11—atopic dermatitis	4.28e-05	0.000475	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR2—atopic dermatitis	4.26e-05	0.000474	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL5—atopic dermatitis	4.18e-05	0.000464	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL10—atopic dermatitis	4.17e-05	0.000463	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NFKBIA—atopic dermatitis	4.13e-05	0.000459	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.08e-05	0.000453	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT6—atopic dermatitis	4.02e-05	0.000447	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD79A—atopic dermatitis	4.01e-05	0.000445	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CCR5—atopic dermatitis	3.94e-05	0.000438	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	3.93e-05	0.000436	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CASP8—atopic dermatitis	3.88e-05	0.000431	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atopic dermatitis	3.8e-05	0.000422	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GLB1—atopic dermatitis	3.65e-05	0.000406	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL5—atopic dermatitis	3.59e-05	0.000399	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL10—atopic dermatitis	3.56e-05	0.000396	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADSL—atopic dermatitis	3.5e-05	0.000389	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR3—atopic dermatitis	3.49e-05	0.000387	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL18—atopic dermatitis	3.28e-05	0.000364	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—atopic dermatitis	3.26e-05	0.000362	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR5—atopic dermatitis	3.23e-05	0.000359	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—atopic dermatitis	3.23e-05	0.000359	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—atopic dermatitis	3.19e-05	0.000354	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GLB1—atopic dermatitis	3.18e-05	0.000354	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TAC1—atopic dermatitis	3.11e-05	0.000345	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NPS—atopic dermatitis	3.11e-05	0.000345	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	3.08e-05	0.000342	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—atopic dermatitis	3.07e-05	0.000341	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PPARA—atopic dermatitis	3.07e-05	0.000341	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL5—atopic dermatitis	3.07e-05	0.00034	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—atopic dermatitis	3.06e-05	0.00034	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADSL—atopic dermatitis	3.05e-05	0.000339	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCR3—atopic dermatitis	3.05e-05	0.000339	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—atopic dermatitis	3.02e-05	0.000336	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—atopic dermatitis	2.9e-05	0.000322	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL5—atopic dermatitis	2.89e-05	0.000321	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NGF—atopic dermatitis	2.84e-05	0.000315	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR5—atopic dermatitis	2.76e-05	0.000307	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—atopic dermatitis	2.73e-05	0.000304	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CCR5—atopic dermatitis	2.73e-05	0.000303	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MAPK8—atopic dermatitis	2.7e-05	0.0003	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	2.66e-05	0.000296	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NFKBIA—atopic dermatitis	2.51e-05	0.000278	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—atopic dermatitis	2.48e-05	0.000275	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL10—atopic dermatitis	2.46e-05	0.000274	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	2.44e-05	0.000271	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—atopic dermatitis	2.42e-05	0.000269	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NFKBIA—atopic dermatitis	2.34e-05	0.00026	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CASP8—atopic dermatitis	2.26e-05	0.000251	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	2.21e-05	0.000245	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL5—atopic dermatitis	2.12e-05	0.000236	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARA—atopic dermatitis	2.06e-05	0.000229	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NGF—atopic dermatitis	1.96e-05	0.000218	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GLB1—atopic dermatitis	1.96e-05	0.000218	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—atopic dermatitis	1.96e-05	0.000217	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—atopic dermatitis	1.95e-05	0.000217	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—atopic dermatitis	1.92e-05	0.000213	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARA—atopic dermatitis	1.91e-05	0.000212	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR5—atopic dermatitis	1.91e-05	0.000212	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADSL—atopic dermatitis	1.88e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—atopic dermatitis	1.87e-05	0.000208	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—atopic dermatitis	1.86e-05	0.000206	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—atopic dermatitis	1.72e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—atopic dermatitis	1.71e-05	0.00019	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—atopic dermatitis	1.71e-05	0.00019	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—atopic dermatitis	1.71e-05	0.00019	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—atopic dermatitis	1.67e-05	0.000185	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKBIA—atopic dermatitis	1.62e-05	0.00018	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—atopic dermatitis	1.6e-05	0.000177	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK8—atopic dermatitis	1.57e-05	0.000175	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK8—atopic dermatitis	1.47e-05	0.000163	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—atopic dermatitis	1.34e-05	0.000149	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARA—atopic dermatitis	1.19e-05	0.000132	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—atopic dermatitis	1.16e-05	0.000128	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—atopic dermatitis	1.1e-05	0.000123	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—atopic dermatitis	1.1e-05	0.000122	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARA—atopic dermatitis	1.03e-05	0.000115	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK8—atopic dermatitis	1.02e-05	0.000113	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—atopic dermatitis	1e-05	0.000111	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—atopic dermatitis	9.38e-06	0.000104	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—atopic dermatitis	9.27e-06	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—atopic dermatitis	6.49e-06	7.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARA—atopic dermatitis	6.37e-06	7.07e-05	CbGpPWpGaD
